ReviewAnnals of gastroenterology
Advances in the development of new biologics in inflammatory bowel disease.
Review in Annals of gastroenterology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- Efficacy and safety of etrolizumab in the treatment of inflammatory bowel disease: a meta-analysis.PeerJ · 2024Pooled it
- Endocannabinoid Levels in Ulcerative Colitis Patients Correlate With Clinical Parameters and Are Affected by Cannabis Consumption.Frontiers in endocrinology · 2021Trial
- Cannabis is associated with clinical but not endoscopic remission in ulcerative colitis: A randomized controlled trial.PloS one · 2021Trial
- Unraveling genetic signatures: the impact of SNPs on therapy response in inflammatory bowel disease patients.Gastroenterology and hepatology from bed to bench · 2025Article
- Development of an Inflammation-Triggered In Vitro "Leaky Gut" Model Using Caco-2/HT29-MTX-E12 Combined with Macrophage-like THP-1 Cells or Primary Human-Derived Macrophages.International journal of molecular sciences · 2023Article
- Acteoside alleviates dextran sulphate sodium‑induced ulcerative colitis via regulation of the HO‑1/HMGB1 signaling pathway.Molecular medicine reports · 2022Article
- Article
- Efficacy and safety of vedolizumab in ulcerative colitis in patients from Asian countries in the GEMINI 1 study.Intestinal research · 2021Article
- Interaction Between Commensal Bacteria, Immune Response and the Intestinal Barrier in Inflammatory Bowel Disease.Frontiers in immunology · 2021Review
- Biologics for the Management of Inflammatory Bowel Disease: A Review in Tuberculosis-Endemic Countries.Gut and liver · 2020Review
- Role of NLRP3 inflammasome in inflammatory bowel diseases.World journal of gastroenterology · 2019Article
- ER stress abrogates the immunosuppressive effect of IL-10 on human macrophages through inhibition of STAT3 activation.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2019Article
- A Real-World Analysis of Prescribing Patterns and Non-persistence of Anti-TNFα Therapy for Inflammatory Bowel Disease.Clinical drug investigation · 2019Article
- Ulcerative Colitis: Shifting Sands.Drugs in R&D · 2019Review
- The inflammatory function of human IgA.Cellular and molecular life sciences : CMLS · 2019Review
- Abnormal brown adipose tissue mitochondrial structure and function in IL10 deficiency.EBioMedicine · 2019Article
- FcαRI co-stimulation converts human intestinal CD103Nature communications · 2018Article
- Fluorescence-mediated Tomography for the Detection and Quantification of Macrophage-related Murine Intestinal Inflammation.Journal of visualized experiments : JoVE · 2017Article
- The Innate and Adaptive Immune System as Targets for Biologic Therapies in Inflammatory Bowel Disease.International journal of molecular sciences · 2017Review
- Detection and characterization of murine colitis and carcinogenesis by molecularly targeted contrast-enhanced ultrasound.World journal of gastroenterology · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Biologics have revolutionized the therapeutic approach in inflammatory bowel disease (IBD). Anti-tumor necrosis factor (anti-TNF) agents infliximab and adalimumab currently constitute the major biological therapy in IBD. Additional anti-TNFs such as golimumab and other new biologics are currently being developed for both anti-TNF-naïve and -resistant patients. These include anti-integrins (vedolizumab and etrolizumab), a JAK inhibitor (tofacitinib) and an anti-anti-interleukin (IL)-23 and IL-12 antibody (ustekinumab), among additional drugs in development. The following review discusses the indications, efficacy and safety issues for these novel medications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.